HONG KONG SAR – EQS Newswire – 16 December \u00a0<\/p>\n \u00a0 \u00a0<\/p>\n BOSHUTAI\u00ae<\/sup> (Acarbose Tablets) Acarbose was first developed Although BOSHUTAI\u00ae<\/sup> HONG KONG SAR – EQS Newswire – 16 December 2020 –\u00a0A fully integrated biopharmaceutical company — Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to announce that BOSHUTAI\u00ae (Acarbose Tablets) has been granted approval for marketing in China by the National Medical Products Administration (“NMPA”) on …<\/p>\n","protected":false},"author":1,"featured_media":10221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/10220"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=10220"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/10220\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media\/10221"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=10220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=10220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=10220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n2020 –\u00a0A fully integrated biopharmaceutical company — Uni-Bio Science Group Limited<\/a> (the
\n“Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK)
\nis pleased to announce that BOSHUTAI\u00ae<\/sup> (Acarbose Tablets)
\nhas been granted approval for marketing in China by the National Medical
\nProducts Administration (“NMPA”) on 10 Nov 2020. The company has also passed
\nGMP manufacturing inspection and is allowed to begin manufacturing of BOSHUTAI\u00ae<\/sup> on 10 December
\n2020. The approvals mean that the Company is qualified to produce and launch
\nBOSHUTAI\u00ae<\/sup> as newly approved generic drug, which marks another
\nmilestone for the Company in the metabolic industry.<\/p>\n![](\"https:\/\/release.media-outreach.com\/release.php\/Images\/Thumb\/400x0\/111994\/p1.jpg#image-111994\")
<\/p>\nUni-bio Science Group CEO Mr. Frank Zhao(left) and
Suzhou Yingli Executive Director Mr. Xu Honglei(right)<\/h5>\n![](\"https:\/\/release.media-outreach.com\/release.php\/Images\/Thumb\/400x0\/112001\/p2.jpg#image-112001\")
<\/p>\nUni-bio Science Group Head of sales and
\nmarketing Mr. An Wen Du given presentation on the commercialization strategy of
\nBOSHUTAI\u00ae<\/h5>\n
\nis the Group’s fifth marketed product following GENETIME\u00ae<\/sup>, GENESOFT\u00ae<\/sup>, PINUP\u00ae<\/sup>, BOKANGTAI\u00ae<\/sup>. Next step, the
\nCompany will focus on the launch and successful commercialization of BOSHUTAI\u00ae<\/sup>.
\nAs manufacturing cost leadership is essential for the success of the product,
\nthe company is already working with a number of strategic partnerships across
\nthe supply chain to ensure BOSHUTAI\u00ae<\/sup> is manufactured at the lowest
\ncost possible. Additionally, the Company successfully held the BOSHUTAI\u00ae<\/sup>
\nlaunch conference on 11 December 2020, where more than 60 commercial partners
\nattended the event. <\/p>\n
\nby Bayer in 1975 and launched in Switzerland in 1986 (trade name: Glucobay\u00ae<\/sup>). As the first
\nFDA-approved alpha-glucosidase inhibitor in the world, it entered China in 1994
\nand is now recommended as a first-line drug for T2D. Acarbose is sold far
\nbetter in China and Asia than in other western countries due to the high
\ncarbohydrate content in Asian cuisine. <\/p>\n
\nis the fifth Acarbose launched in China, the Group is still confident in taking
\nmarket share for two reasons. Firstly, Acarbose has been marketed in China for
\nmore than 20 years, China’s Acarbose market is dominated by Glucobay\u00ae<\/sup>.
\nNevertheless, in recent years, the market share of Glucobay\u00ae<\/sup> is rapidly
\ndeclining, while the market share of domestic-made counterparts is rising due
\nto more affordable pricing. Moreover, BOSHUTAI\u00ae<\/sup> is expected to be
\nincluded in the next national drug volume-based procurement, the stable supply of API and Acarbose Market
\nAuthorization Holder (“MAH”) strategy of the Group enables Acarbose cost
\nleadership and decreases supply chain risk in the future. It is expected that
\nat least three companies can potentially win the national procurement, where
\neach winner enjoys approximately 30% market share of the whole centralized
\nprocurement market. According to the Chinese public healthcare institute sales
\ndata, Acarbose reached RMB 8.4 billion in sales in 2018, growing at
\ndouble-digit CAGR in the past five years. If the Group successfully implements
\nits strategy and win the national procurement, BOSHUTAI\u00ae<\/sup> will
\nsignificantly and positively impact revenue in the coming few years.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"